Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Post by Pandoraon Nov 24, 2021 10:00am
974 Views
Post# 34161022

Award News

Award News
oronto, Ontario – TheNewswire – November 24, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that Ventripoint will be highlighted as one of Life Sciences Ontario (LSO) 2021 Success Stories (https://lifesciencesontario.ca/reports-and-publications/).The LSO campaign aims to highlight companies and institutions that are creating innovative solutions in the life science sector.

The LSO is a member-funded, non-for-profit organization that works to advance advocacy and policy work, education and networking events, and support services for the life sciences sector. As part of the campaign, Ventripoint’s story will be distributed at LSO Queens Park meetings where MPPs are engaged on future policy development as an example of innovation that improves healthcare in a more cost-effective manner.

"Ontario's life sciences industry is dedicated to bringing new innovations to improve the lives of all Canadians. Success stories, like Ventripoint Diagnostics, show how scientific discoveries can be turned into real-world solutions; while creating jobs and prosperity here in Ontario," Dr. Jason Field, CEO, and President of Life Sciences Ontario.

The VMS+ is the first cost effective and accurate system for measuring the function all four chambers of the heart. This initiative will help to bring brand awareness and spread the word about Ventripoint’s innovative solution to improve cardiac diagnosis for everyone worldwide and especially for children.

About Life Sciences Ontario

LSO’s mission is to foster commercial success for Ontario’s life sciences sector through advocacy and education, and promoting the industry locally, nationally, and internationally. The LSO works to increase the profile of Ontario’s Life Sciences sector to secure economic and social prosperity. The organization’s education around successful companies within the sector facilitates will support the growth and development of the life science sector.

<< Previous
Bullboard Posts
Next >>